论文部分内容阅读
目的观察紫杉醇联合氟尿嘧啶、顺铂治疗晚期胃癌的临床疗效及毒副反应。方法 51例晚期胃癌患者随机以紫杉醇联合氟尿嘧啶、顺铂的方案或表柔比星联合氟尿嘧啶、顺铂的方案化疗,均化疗2个周期以上。每个周期28 d。结果紫杉醇联合氟尿嘧啶、顺铂方案的有效率(CR+PR)为51.9%,毒副反应有神经毒性、脱发、关节肌肉疼痛及血液学毒性,胃肠道反应发生率为51.8%。表柔比星联合氟尿嘧啶、顺铂方案的有效率(CR+PR)为50.0%,有脱发、心肌毒性、血液学毒性,胃肠道反应发生率为87.5%。结论紫杉醇联合氟尿嘧啶、顺铂治疗晚期胃癌与表柔比星联合氟尿嘧啶、顺铂治疗晚期胃癌相比,副反应均可耐受,但胃肠道反应相对较轻,疗效相当。
Objective To observe the clinical efficacy and side effects of paclitaxel combined with 5-fluorouracil and cisplatin in the treatment of advanced gastric cancer. Methods Totally 51 patients with advanced gastric cancer were treated with paclitaxel plus fluorouracil and cisplatin or epirubicin combined with fluorouracil and cisplatin for more than 2 cycles. 28 days per cycle. Results The effective rate (CR + PR) of paclitaxel combined with fluorouracil and cisplatin was 51.9%. The toxic and side effects were neurotoxic, alopecia, joint and muscle pain and hematological toxicity. The incidence of gastrointestinal reaction was 51.8%. The effective rate (CR + PR) of epirubicin combined with fluorouracil and cisplatin was 50.0%. The incidence of alopecia, cardiotoxicity, hematologic toxicity and gastrointestinal reaction was 87.5%. Conclusions Both paclitaxel and fluorouracil combined with cisplatin are superior to epirubicin in the treatment of advanced gastric cancer and epirubicin in combination with fluorouracil and cisplatin in the treatment of advanced gastric cancer. However, the gastrointestinal reactions are relatively mild with comparable efficacy.